If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Expands patient reach to remotest towns by furthering investment in GoApptiv
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Subscribe To Our Newsletter & Stay Updated
